ZA200205300B - Heteroaromatic carboxamide derivatives and their use as inhibitors of the enzyme IKK-2. - Google Patents
Heteroaromatic carboxamide derivatives and their use as inhibitors of the enzyme IKK-2. Download PDFInfo
- Publication number
- ZA200205300B ZA200205300B ZA200205300A ZA200205300A ZA200205300B ZA 200205300 B ZA200205300 B ZA 200205300B ZA 200205300 A ZA200205300 A ZA 200205300A ZA 200205300 A ZA200205300 A ZA 200205300A ZA 200205300 B ZA200205300 B ZA 200205300B
- Authority
- ZA
- South Africa
- Prior art keywords
- amino
- thiophenecarboxamide
- aminocarbonyl
- compound
- methyl
- Prior art date
Links
- 125000001072 heteroaryl group Chemical group 0.000 title claims description 13
- 102000004190 Enzymes Human genes 0.000 title description 5
- 108090000790 Enzymes Proteins 0.000 title description 5
- 229940053202 antiepileptics carboxamide derivative Drugs 0.000 title description 3
- 239000003112 inhibitor Substances 0.000 title description 3
- 238000000034 method Methods 0.000 claims abstract description 39
- -1 heteroaromatic carboxamides Chemical class 0.000 claims abstract description 16
- 230000008569 process Effects 0.000 claims abstract description 15
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 9
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims description 99
- 150000001875 compounds Chemical class 0.000 claims description 80
- 150000003839 salts Chemical class 0.000 claims description 43
- 229910052799 carbon Inorganic materials 0.000 claims description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 29
- 201000010099 disease Diseases 0.000 claims description 27
- 125000000217 alkyl group Chemical group 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 23
- 239000012453 solvate Substances 0.000 claims description 22
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 16
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 16
- 229910052760 oxygen Inorganic materials 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 15
- 238000006243 chemical reaction Methods 0.000 claims description 13
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 12
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Chemical group C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 12
- 239000001301 oxygen Substances 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- 229910052717 sulfur Inorganic materials 0.000 claims description 11
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 9
- 102100021854 Inhibitor of nuclear factor kappa-B kinase subunit beta Human genes 0.000 claims description 9
- 101710205525 Inhibitor of nuclear factor kappa-B kinase subunit beta Proteins 0.000 claims description 9
- 150000002367 halogens Chemical class 0.000 claims description 9
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical group C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 8
- 125000005842 heteroatom Chemical group 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 239000011593 sulfur Substances 0.000 claims description 8
- YNSCKPCDFIDINW-UHFFFAOYSA-N 3-[[2-[[1-[2-(dimethylamino)acetyl]-6-methoxy-4,4-dimethyl-2,3-dihydroquinolin-7-yl]amino]-7h-pyrrolo[2,3-d]pyrimidin-4-yl]amino]thiophene-2-carboxamide Chemical compound COC1=CC(C(CCN2C(=O)CN(C)C)(C)C)=C2C=C1NC(N=C1NC=CC1=1)=NC=1NC=1C=CSC=1C(N)=O YNSCKPCDFIDINW-UHFFFAOYSA-N 0.000 claims description 7
- 125000003545 alkoxy group Chemical group 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 208000027866 inflammatory disease Diseases 0.000 claims description 6
- 229910052751 metal Inorganic materials 0.000 claims description 6
- 239000002184 metal Substances 0.000 claims description 6
- 238000011321 prophylaxis Methods 0.000 claims description 6
- 229930192474 thiophene Natural products 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 5
- 230000009286 beneficial effect Effects 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 230000005764 inhibitory process Effects 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- 230000003287 optical effect Effects 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- HRBQTGKEMAVNDB-UHFFFAOYSA-N 3-(carbamoylamino)-5-(3-chlorophenyl)thiophene-2-carboxamide Chemical compound S1C(C(N)=O)=C(NC(=O)N)C=C1C1=CC=CC(Cl)=C1 HRBQTGKEMAVNDB-UHFFFAOYSA-N 0.000 claims description 4
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- GXLMJTMAQFBLSR-UHFFFAOYSA-N 3-(carbamoylamino)-5-(2-chlorophenyl)thiophene-2-carboxamide Chemical compound S1C(C(N)=O)=C(NC(=O)N)C=C1C1=CC=CC=C1Cl GXLMJTMAQFBLSR-UHFFFAOYSA-N 0.000 claims description 3
- AZFVZMKCOBJRAW-UHFFFAOYSA-N 3-(carbamoylamino)-5-thiophen-3-ylthiophene-2-carboxamide Chemical compound S1C(C(N)=O)=C(NC(=O)N)C=C1C1=CSC=C1 AZFVZMKCOBJRAW-UHFFFAOYSA-N 0.000 claims description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 claims description 3
- 125000000304 alkynyl group Chemical group 0.000 claims description 3
- 125000001589 carboacyl group Chemical group 0.000 claims description 3
- 239000012948 isocyanate Substances 0.000 claims description 3
- 150000002513 isocyanates Chemical class 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- ATBVEMCPWCNKAL-UHFFFAOYSA-N 2-(carbamothioylamino)-5-phenylthiophene-3-carboxamide Chemical compound NC(=O)C1=C(NC(=S)N)SC(C=2C=CC=CC=2)=C1 ATBVEMCPWCNKAL-UHFFFAOYSA-N 0.000 claims description 2
- QQZVZIZPJRWDJD-UHFFFAOYSA-N 2-(carbamoylamino)-4-methyl-5-phenylthiophene-3-carboxamide Chemical compound S1C(NC(N)=O)=C(C(N)=O)C(C)=C1C1=CC=CC=C1 QQZVZIZPJRWDJD-UHFFFAOYSA-N 0.000 claims description 2
- CLPFREPZDLOUQD-UHFFFAOYSA-N 2-(carbamoylamino)-5-(3,5-dimethyl-1,2-oxazol-4-yl)thiophene-3-carboxamide Chemical compound CC1=NOC(C)=C1C1=CC(C(N)=O)=C(NC(N)=O)S1 CLPFREPZDLOUQD-UHFFFAOYSA-N 0.000 claims description 2
- XDWCHVTXXSDZPW-UHFFFAOYSA-N 2-(carbamoylamino)-5-(4-hydroxyphenyl)-4-methylthiophene-3-carboxamide Chemical compound NC(=O)C1=C(NC(N)=O)SC(C=2C=CC(O)=CC=2)=C1C XDWCHVTXXSDZPW-UHFFFAOYSA-N 0.000 claims description 2
- KLTHOXLEZZZIKF-UHFFFAOYSA-N 2-(carbamoylamino)-5-(4-methoxy-3-methylphenyl)-4-methylthiophene-3-carboxamide Chemical compound C1=C(C)C(OC)=CC=C1C1=C(C)C(C(N)=O)=C(NC(N)=O)S1 KLTHOXLEZZZIKF-UHFFFAOYSA-N 0.000 claims description 2
- COYICBSHVUAHQG-UHFFFAOYSA-N 2-(carbamoylamino)-5-(4-methoxyphenyl)-4-methylthiophene-3-carboxamide Chemical compound C1=CC(OC)=CC=C1C1=C(C)C(C(N)=O)=C(NC(N)=O)S1 COYICBSHVUAHQG-UHFFFAOYSA-N 0.000 claims description 2
- LNMXHBQGPRUADI-UHFFFAOYSA-N 2-(carbamoylamino)-5-(4-methylsulfonylphenyl)thiophene-3-carboxamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC(C(N)=O)=C(NC(N)=O)S1 LNMXHBQGPRUADI-UHFFFAOYSA-N 0.000 claims description 2
- BDZUXXVCUNXOPR-UHFFFAOYSA-N 2-(carbamoylamino)-5-(furan-2-yl)thiophene-3-carboxamide Chemical compound NC(=O)C1=C(NC(=O)N)SC(C=2OC=CC=2)=C1 BDZUXXVCUNXOPR-UHFFFAOYSA-N 0.000 claims description 2
- NRRMPQZZBHIDOC-UHFFFAOYSA-N 2-(carbamoylamino)-5-[4-(trifluoromethyl)phenyl]thiophene-3-carboxamide Chemical compound NC(=O)C1=C(NC(=O)N)SC(C=2C=CC(=CC=2)C(F)(F)F)=C1 NRRMPQZZBHIDOC-UHFFFAOYSA-N 0.000 claims description 2
- SMJJKGGHJUSUHR-UHFFFAOYSA-N 2-(carbamoylamino)-5-phenyl-4-(trifluoromethyl)thiophene-3-carboxamide Chemical compound NC(=O)C1=C(NC(=O)N)SC(C=2C=CC=CC=2)=C1C(F)(F)F SMJJKGGHJUSUHR-UHFFFAOYSA-N 0.000 claims description 2
- PSVUSJKZJQMCSP-UHFFFAOYSA-N 2-(carbamoylamino)-5-phenylthiophene-3-carboxamide Chemical compound NC(=O)C1=C(NC(=O)N)SC(C=2C=CC=CC=2)=C1 PSVUSJKZJQMCSP-UHFFFAOYSA-N 0.000 claims description 2
- UUGTXTYLCCKUTO-UHFFFAOYSA-N 2-(carbamoylamino)-5-pyridin-2-ylthiophene-3-carboxamide Chemical compound NC(=O)C1=C(NC(=O)N)SC(C=2N=CC=CC=2)=C1 UUGTXTYLCCKUTO-UHFFFAOYSA-N 0.000 claims description 2
- IZDMGIFTGJJRIC-UHFFFAOYSA-N 3-(carbamoylamino)-5-(2-methoxyphenyl)thiophene-2-carboxamide Chemical compound COC1=CC=CC=C1C1=CC(NC(N)=O)=C(C(N)=O)S1 IZDMGIFTGJJRIC-UHFFFAOYSA-N 0.000 claims description 2
- GIDGPFNZBRRNRV-UHFFFAOYSA-N 3-(carbamoylamino)-5-(3-hydroxyphenyl)thiophene-2-carboxamide Chemical compound S1C(C(N)=O)=C(NC(=O)N)C=C1C1=CC=CC(O)=C1 GIDGPFNZBRRNRV-UHFFFAOYSA-N 0.000 claims description 2
- QVAASXDKTFEGRJ-UHFFFAOYSA-N 3-(carbamoylamino)-5-(4-fluorophenyl)thiophene-2-carboxamide Chemical compound S1C(C(N)=O)=C(NC(=O)N)C=C1C1=CC=C(F)C=C1 QVAASXDKTFEGRJ-UHFFFAOYSA-N 0.000 claims description 2
- PYQXCBITORSUDH-UHFFFAOYSA-N 3-(carbamoylamino)-5-(4-methoxyphenyl)thiophene-2-carboxamide Chemical compound C1=CC(OC)=CC=C1C1=CC(NC(N)=O)=C(C(N)=O)S1 PYQXCBITORSUDH-UHFFFAOYSA-N 0.000 claims description 2
- BGGFWIFMCIWSLU-UHFFFAOYSA-N 3-(carbamoylamino)-5-[2-(2-piperidin-1-ylethoxy)phenyl]thiophene-2-carboxamide Chemical compound S1C(C(N)=O)=C(NC(=O)N)C=C1C1=CC=CC=C1OCCN1CCCCC1 BGGFWIFMCIWSLU-UHFFFAOYSA-N 0.000 claims description 2
- XMWDYFPXVMZZQN-UHFFFAOYSA-N 3-(carbamoylamino)-5-[3-[2-(dimethylamino)ethoxy]phenyl]thiophene-2-carboxamide Chemical compound CN(C)CCOC1=CC=CC(C=2SC(=C(NC(N)=O)C=2)C(N)=O)=C1 XMWDYFPXVMZZQN-UHFFFAOYSA-N 0.000 claims description 2
- UBGJXCDOCIXCJC-UHFFFAOYSA-N 3-(carbamoylamino)-5-[4-(2-methylpropyl)phenyl]thiophene-2-carboxamide Chemical compound C1=CC(CC(C)C)=CC=C1C1=CC(NC(N)=O)=C(C(N)=O)S1 UBGJXCDOCIXCJC-UHFFFAOYSA-N 0.000 claims description 2
- XZJDTLHIAQZDKI-UHFFFAOYSA-N 3-(carbamoylamino)-5-[4-(2-piperidin-1-ylethoxy)phenyl]thiophene-2-carboxamide Chemical compound S1C(C(N)=O)=C(NC(=O)N)C=C1C(C=C1)=CC=C1OCCN1CCCCC1 XZJDTLHIAQZDKI-UHFFFAOYSA-N 0.000 claims description 2
- ZDQLZTAJWGOWEF-UHFFFAOYSA-N 3-(carbamoylamino)-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]thiophene-2-carboxamide Chemical compound S1C(C(N)=O)=C(NC(=O)N)C=C1C(C=C1)=CC=C1OCCN1CCCC1 ZDQLZTAJWGOWEF-UHFFFAOYSA-N 0.000 claims description 2
- 239000005864 Sulphur Chemical group 0.000 claims description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 150000002540 isothiocyanates Chemical class 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 125000002971 oxazolyl group Chemical group 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 12
- 125000003870 2-(1-piperidinyl)ethoxy group Chemical group [*]OC([H])([H])C([H])([H])N1C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- LKQKGDYZKYZRSA-UHFFFAOYSA-N 2-(carbamoylamino)-4-methyl-5-pyridin-2-ylthiophene-3-carboxamide Chemical compound NC(=O)C1=C(NC(N)=O)SC(C=2N=CC=CC=2)=C1C LKQKGDYZKYZRSA-UHFFFAOYSA-N 0.000 claims 1
- JPGGOSHIXLWTIQ-UHFFFAOYSA-N 2-(carbamoylamino)-5-(1h-pyrrol-2-yl)thiophene-3-carboxamide Chemical compound NC(=O)C1=C(NC(=O)N)SC(C=2NC=CC=2)=C1 JPGGOSHIXLWTIQ-UHFFFAOYSA-N 0.000 claims 1
- FAMJKPLELMLHSY-UHFFFAOYSA-N 2-(carbamoylamino)-5-(3,4-dichlorophenyl)-4-methylthiophene-3-carboxamide Chemical compound NC(=O)C1=C(NC(N)=O)SC(C=2C=C(Cl)C(Cl)=CC=2)=C1C FAMJKPLELMLHSY-UHFFFAOYSA-N 0.000 claims 1
- WOCVVZHRWJHXPQ-UHFFFAOYSA-N 2-(carbamoylamino)-5-(3-fluorophenyl)-4-methylthiophene-3-carboxamide Chemical compound NC(=O)C1=C(NC(N)=O)SC(C=2C=C(F)C=CC=2)=C1C WOCVVZHRWJHXPQ-UHFFFAOYSA-N 0.000 claims 1
- FVBQZSLVARNBKI-UHFFFAOYSA-N 2-(carbamoylamino)-5-(3-methoxyphenyl)-4-methylthiophene-3-carboxamide Chemical compound COC1=CC=CC(C2=C(C(C(N)=O)=C(NC(N)=O)S2)C)=C1 FVBQZSLVARNBKI-UHFFFAOYSA-N 0.000 claims 1
- WPYPRHJBDHULLS-UHFFFAOYSA-N 2-(carbamoylamino)-5-(4-chlorophenyl)thiophene-3-carboxamide Chemical compound NC(=O)C1=C(NC(=O)N)SC(C=2C=CC(Cl)=CC=2)=C1 WPYPRHJBDHULLS-UHFFFAOYSA-N 0.000 claims 1
- LNPHMBRNCVPNDD-UHFFFAOYSA-N 2-(carbamoylamino)-5-(4-cyanophenyl)-4-methylthiophene-3-carboxamide Chemical compound S1C(NC(N)=O)=C(C(N)=O)C(C)=C1C1=CC=C(C#N)C=C1 LNPHMBRNCVPNDD-UHFFFAOYSA-N 0.000 claims 1
- TZNIVANCRGBJFY-UHFFFAOYSA-N 3-(carbamoylamino)-5-(3-methoxyphenyl)thiophene-2-carboxamide Chemical compound COC1=CC=CC(C=2SC(=C(NC(N)=O)C=2)C(N)=O)=C1 TZNIVANCRGBJFY-UHFFFAOYSA-N 0.000 claims 1
- CYEQODIYTZSLEN-UHFFFAOYSA-N 3-(carbamoylamino)-5-[4-[2-(dimethylamino)ethoxy]phenyl]thiophene-2-carboxamide Chemical compound C1=CC(OCCN(C)C)=CC=C1C1=CC(NC(N)=O)=C(C(N)=O)S1 CYEQODIYTZSLEN-UHFFFAOYSA-N 0.000 claims 1
- HKWYRLYHYBFHLL-UHFFFAOYSA-N 3-(carbamoylamino)-5-phenylthiophene-2-carboxamide Chemical compound S1C(C(N)=O)=C(NC(=O)N)C=C1C1=CC=CC=C1 HKWYRLYHYBFHLL-UHFFFAOYSA-N 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- DSNYFFJTZPIKFZ-UHFFFAOYSA-N propoxybenzene Chemical group CCCOC1=CC=CC=C1 DSNYFFJTZPIKFZ-UHFFFAOYSA-N 0.000 claims 1
- 239000000543 intermediate Substances 0.000 abstract description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- NIZHERJWXFHGGU-UHFFFAOYSA-N isocyanato(trimethyl)silane Chemical compound C[Si](C)(C)N=C=O NIZHERJWXFHGGU-UHFFFAOYSA-N 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 230000026731 phosphorylation Effects 0.000 description 6
- 238000006366 phosphorylation reaction Methods 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- ZVCDLGYNFYZZOK-UHFFFAOYSA-M sodium cyanate Chemical compound [Na]OC#N ZVCDLGYNFYZZOK-UHFFFAOYSA-M 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- GRNOZCCBOFGDCL-UHFFFAOYSA-N 2,2,2-trichloroacetyl isocyanate Chemical compound ClC(Cl)(Cl)C(=O)N=C=O GRNOZCCBOFGDCL-UHFFFAOYSA-N 0.000 description 2
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 102100033115 Mitogen-activated protein kinase kinase kinase 1 Human genes 0.000 description 2
- 101710164423 Mitogen-activated protein kinase kinase kinase 1 Proteins 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 102000036646 Signalosomes Human genes 0.000 description 2
- 108091007411 Signalosomes Proteins 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- WRJWRGBVPUUDLA-UHFFFAOYSA-N chlorosulfonyl isocyanate Chemical compound ClS(=O)(=O)N=C=O WRJWRGBVPUUDLA-UHFFFAOYSA-N 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 125000002346 iodo group Chemical group I* 0.000 description 2
- WLPWFUWQZRXIFA-UHFFFAOYSA-N methyl 3-amino-5-(3-chlorophenyl)thiophene-2-carboxylate Chemical compound NC1=C(C(=O)OC)SC(C=2C=C(Cl)C=CC=2)=C1 WLPWFUWQZRXIFA-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- UUWJBXKHMMQDED-UHFFFAOYSA-N 1-(3-chlorophenyl)ethanone Chemical compound CC(=O)C1=CC=CC(Cl)=C1 UUWJBXKHMMQDED-UHFFFAOYSA-N 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- SDLHAVROROHUBG-UHFFFAOYSA-N 2-(carbamoylamino)-4-ethyl-5-phenylthiophene-3-carboxamide Chemical compound NC(=O)C1=C(NC(N)=O)SC(C=2C=CC=CC=2)=C1CC SDLHAVROROHUBG-UHFFFAOYSA-N 0.000 description 1
- XGWCGJSJBKWZMI-UHFFFAOYSA-N 2-(carbamoylamino)-4-methyl-5-(3,4,5-trimethoxyphenyl)thiophene-3-carboxamide Chemical compound COC1=C(OC)C(OC)=CC(C2=C(C(C(N)=O)=C(NC(N)=O)S2)C)=C1 XGWCGJSJBKWZMI-UHFFFAOYSA-N 0.000 description 1
- JPWRQYSXPRDVAA-UHFFFAOYSA-N 2-(carbamoylamino)-4-methyl-5-(4-propan-2-ylphenyl)thiophene-3-carboxamide Chemical compound C1=CC(C(C)C)=CC=C1C1=C(C)C(C(N)=O)=C(NC(N)=O)S1 JPWRQYSXPRDVAA-UHFFFAOYSA-N 0.000 description 1
- CXTHSHHAIJQMJR-UHFFFAOYSA-N 2-(carbamoylamino)-4-methyl-5-[4-(2-piperidin-1-ylethoxy)phenyl]thiophene-3-carboxamide Chemical compound S1C(NC(N)=O)=C(C(N)=O)C(C)=C1C(C=C1)=CC=C1OCCN1CCCCC1 CXTHSHHAIJQMJR-UHFFFAOYSA-N 0.000 description 1
- NSKPLVBPTNICMU-UHFFFAOYSA-N 2-(carbamoylamino)-4-methyl-5-pyrimidin-4-ylthiophene-3-carboxamide Chemical compound NC(=O)C1=C(NC(N)=O)SC(C=2N=CN=CC=2)=C1C NSKPLVBPTNICMU-UHFFFAOYSA-N 0.000 description 1
- NHNDJPHJRKXSPD-UHFFFAOYSA-N 2-(carbamoylamino)-5-(2-chlorophenyl)-4-methylthiophene-3-carboxamide Chemical compound NC(=O)C1=C(NC(N)=O)SC(C=2C(=CC=CC=2)Cl)=C1C NHNDJPHJRKXSPD-UHFFFAOYSA-N 0.000 description 1
- MXKGBJSUVPWHTE-UHFFFAOYSA-N 2-(carbamoylamino)-5-(3,5-dimethoxyphenyl)-4-methylthiophene-3-carboxamide Chemical compound COC1=CC(OC)=CC(C2=C(C(C(N)=O)=C(NC(N)=O)S2)C)=C1 MXKGBJSUVPWHTE-UHFFFAOYSA-N 0.000 description 1
- AXXSGOUYJMRDBJ-UHFFFAOYSA-N 2-(carbamoylamino)-5-(furan-3-yl)thiophene-3-carboxamide Chemical compound NC(=O)C1=C(NC(=O)N)SC(C2=COC=C2)=C1 AXXSGOUYJMRDBJ-UHFFFAOYSA-N 0.000 description 1
- UQXDOVBNWLUIAF-UHFFFAOYSA-N 2-(carbamoylamino)-5-[4-(1,3-thiazol-4-ylmethoxy)phenyl]thiophene-3-carboxamide Chemical compound NC(=O)C1=C(NC(=O)N)SC(C=2C=CC(OCC=3N=CSC=3)=CC=2)=C1 UQXDOVBNWLUIAF-UHFFFAOYSA-N 0.000 description 1
- FLGCIFCXVAFWLT-UHFFFAOYSA-N 2-(carbamoylamino)-5-pyridin-3-ylthiophene-3-carboxamide Chemical compound NC(=O)C1=C(NC(=O)N)SC(C=2C=NC=CC=2)=C1 FLGCIFCXVAFWLT-UHFFFAOYSA-N 0.000 description 1
- XEFCHXAXZNYWJN-UHFFFAOYSA-N 2-(carbamoylamino)-5-pyrimidin-5-ylthiophene-3-carboxamide Chemical compound NC(=O)C1=C(NC(=O)N)SC(C=2C=NC=NC=2)=C1 XEFCHXAXZNYWJN-UHFFFAOYSA-N 0.000 description 1
- SLONXLUFWDCEBJ-UHFFFAOYSA-N 3-(carbamoylamino)-5-[3-(2-pyrrolidin-1-ylethoxy)phenyl]thiophene-2-carboxamide Chemical compound S1C(C(N)=O)=C(NC(=O)N)C=C1C1=CC=CC(OCCN2CCCC2)=C1 SLONXLUFWDCEBJ-UHFFFAOYSA-N 0.000 description 1
- ISQCRQWKOUIVGG-UHFFFAOYSA-N 3-amino-5-(2-chlorophenyl)thiophene-2-carboxamide Chemical compound NC1=C(C(=O)N)SC(C=2C(=CC=CC=2)Cl)=C1 ISQCRQWKOUIVGG-UHFFFAOYSA-N 0.000 description 1
- VVGHAKCFYWLLBG-UHFFFAOYSA-N 3-amino-5-(2-chlorophenyl)thiophene-2-carboxylic acid Chemical compound S1C(C(O)=O)=C(N)C=C1C1=CC=CC=C1Cl VVGHAKCFYWLLBG-UHFFFAOYSA-N 0.000 description 1
- QXIRLNPWLNFJJX-UHFFFAOYSA-N 3-amino-5-(3-chlorophenyl)thiophene-2-carboxamide Chemical compound NC1=C(C(=O)N)SC(C=2C=C(Cl)C=CC=2)=C1 QXIRLNPWLNFJJX-UHFFFAOYSA-N 0.000 description 1
- AODRZWRPMMTRML-UHFFFAOYSA-N 3-amino-5-(3-chlorophenyl)thiophene-2-carboxamide;3-amino-5-(3-chlorophenyl)thiophene-2-carboxylic acid Chemical compound NC1=C(C(=O)N)SC(C=2C=C(Cl)C=CC=2)=C1.S1C(C(O)=O)=C(N)C=C1C1=CC=CC(Cl)=C1 AODRZWRPMMTRML-UHFFFAOYSA-N 0.000 description 1
- BCMFIXZCLJBTAQ-UHFFFAOYSA-N 3-amino-5-(3-chlorophenyl)thiophene-2-carboxylic acid Chemical compound S1C(C(O)=O)=C(N)C=C1C1=CC=CC(Cl)=C1 BCMFIXZCLJBTAQ-UHFFFAOYSA-N 0.000 description 1
- BMUACLADCKCNKZ-UHFFFAOYSA-N 3-amino-5-(3-thiophenyl)-2-thiophenecarboxamide Chemical compound NC1=C(C(=O)N)SC(C2=CSC=C2)=C1 BMUACLADCKCNKZ-UHFFFAOYSA-N 0.000 description 1
- MQYJPACEBWKWEH-UHFFFAOYSA-N 3-amino-5-(4-chlorophenyl)thiophene-2-carboxamide Chemical compound NC1=C(C(=O)N)SC(C=2C=CC(Cl)=CC=2)=C1 MQYJPACEBWKWEH-UHFFFAOYSA-N 0.000 description 1
- VRUAXQODZDRLMI-UHFFFAOYSA-N 3-amino-5-(4-fluorophenyl)thiophene-2-carboxamide Chemical compound NC1=C(C(=O)N)SC(C=2C=CC(F)=CC=2)=C1 VRUAXQODZDRLMI-UHFFFAOYSA-N 0.000 description 1
- OEUITKOCUWEFOB-UHFFFAOYSA-N 3-amino-5-(4-methoxyphenyl)thiophene-2-carboxamide Chemical compound C1=CC(OC)=CC=C1C1=CC(N)=C(C(N)=O)S1 OEUITKOCUWEFOB-UHFFFAOYSA-N 0.000 description 1
- YFLAQQQXQJSDOS-UHFFFAOYSA-N 3-amino-5-thiophen-2-ylthiophene-2-carboxamide Chemical compound NC1=C(C(=O)N)SC(C=2SC=CC=2)=C1 YFLAQQQXQJSDOS-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- OJSUVLRFSLPFGL-UHFFFAOYSA-N 5-(carbamoylamino)-2-(3,5-dichlorophenyl)-1,3-oxazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)N)OC(C=2C=C(Cl)C=C(Cl)C=2)=N1 OJSUVLRFSLPFGL-UHFFFAOYSA-N 0.000 description 1
- WQAOYOSIGJNDHS-UHFFFAOYSA-N 5-(carbamoylamino)-2-[4-(trifluoromethyl)phenyl]-1,3-oxazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)N)OC(C=2C=CC(=CC=2)C(F)(F)F)=N1 WQAOYOSIGJNDHS-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- LZJRNLRASBVRRX-ZDUSSCGKSA-N Boldine Chemical compound CN1CCC2=CC(O)=C(OC)C3=C2[C@@H]1CC1=C3C=C(OC)C(O)=C1 LZJRNLRASBVRRX-ZDUSSCGKSA-N 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 101100347633 Drosophila melanogaster Mhc gene Proteins 0.000 description 1
- 102100039246 Elongator complex protein 1 Human genes 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 101000813117 Homo sapiens Elongator complex protein 1 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 101000850748 Homo sapiens Tumor necrosis factor receptor type 1-associated DEATH domain protein Proteins 0.000 description 1
- 101001087394 Homo sapiens Tyrosine-protein phosphatase non-receptor type 1 Proteins 0.000 description 1
- 208000024781 Immune Complex disease Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241001490312 Lithops pseudotruncatella Species 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- YXOLAZRVSSWPPT-UHFFFAOYSA-N Morin Chemical compound OC1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 YXOLAZRVSSWPPT-UHFFFAOYSA-N 0.000 description 1
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 1
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 1
- BTJRFZITEZGSDU-UHFFFAOYSA-N NC1=C(SC(=C1)C1=CC(=CC=C1)OC)C(=O)N.NC(=O)NC1=C(SC(=C1)C1=CC(=CC=C1)O)C(=O)N Chemical compound NC1=C(SC(=C1)C1=CC(=CC=C1)OC)C(=O)N.NC(=O)NC1=C(SC(=C1)C1=CC(=CC=C1)O)C(=O)N BTJRFZITEZGSDU-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101100002888 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) asa-1 gene Proteins 0.000 description 1
- 241000042032 Petrocephalus catostoma Species 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 201000002661 Spondylitis Diseases 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 102100033081 Tumor necrosis factor receptor type 1-associated DEATH domain protein Human genes 0.000 description 1
- 102000018594 Tumour necrosis factor Human genes 0.000 description 1
- 108050007852 Tumour necrosis factor Proteins 0.000 description 1
- 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000008107 benzenesulfonic acids Chemical class 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- XLTUPERVRFLGLJ-UHFFFAOYSA-N isothiocyanato(trimethyl)silane Chemical compound C[Si](C)(C)N=C=S XLTUPERVRFLGLJ-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
- MKIJJIMOAABWGF-UHFFFAOYSA-N methyl 2-sulfanylacetate Chemical compound COC(=O)CS MKIJJIMOAABWGF-UHFFFAOYSA-N 0.000 description 1
- YIQJFQMRWXPBSJ-UHFFFAOYSA-N methyl 3-amino-5-(2-chlorophenyl)thiophene-2-carboxylate Chemical compound NC1=C(C(=O)OC)SC(C=2C(=CC=CC=2)Cl)=C1 YIQJFQMRWXPBSJ-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 235000007708 morin Nutrition 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 102000030938 small GTPase Human genes 0.000 description 1
- 108060007624 small GTPase Proteins 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 239000011135 tin Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- GRGCWBWNLSTIEN-UHFFFAOYSA-N trifluoromethanesulfonyl chloride Chemical compound FC(F)(F)S(Cl)(=O)=O GRGCWBWNLSTIEN-UHFFFAOYSA-N 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D333/40—Thiophene-2-carboxylic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0003154.2A GB0003154D0 (en) | 2000-02-12 | 2000-02-12 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200205300B true ZA200205300B (en) | 2003-10-02 |
Family
ID=9885396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200205300A ZA200205300B (en) | 2000-02-12 | 2002-07-02 | Heteroaromatic carboxamide derivatives and their use as inhibitors of the enzyme IKK-2. |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US7358376B2 (enExample) |
| EP (1) | EP1261600B1 (enExample) |
| JP (1) | JP4812999B2 (enExample) |
| KR (1) | KR100738165B1 (enExample) |
| CN (1) | CN1243747C (enExample) |
| AT (1) | ATE266019T1 (enExample) |
| AU (1) | AU781047B2 (enExample) |
| BR (1) | BR0108143A (enExample) |
| CA (1) | CA2396824C (enExample) |
| DE (1) | DE60103132T2 (enExample) |
| DK (1) | DK1261600T3 (enExample) |
| ES (1) | ES2218376T3 (enExample) |
| GB (1) | GB0003154D0 (enExample) |
| IL (2) | IL150482A0 (enExample) |
| MX (1) | MXPA02007734A (enExample) |
| NO (1) | NO327741B1 (enExample) |
| NZ (1) | NZ519947A (enExample) |
| PT (1) | PT1261600E (enExample) |
| TR (1) | TR200401962T4 (enExample) |
| WO (1) | WO2001058890A1 (enExample) |
| ZA (1) | ZA200205300B (enExample) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6869956B2 (en) | 2000-10-03 | 2005-03-22 | Bristol-Myers Squibb Company | Methods of treating inflammatory and immune diseases using inhibitors of IκB kinase (IKK) |
| JP2004523476A (ja) * | 2000-10-12 | 2004-08-05 | スミスクライン・ビーチャム・コーポレイション | ＮＦ−κＢ阻害剤 |
| CA2427284A1 (en) | 2000-10-26 | 2002-05-30 | Tularik Inc. | Antiinflammation agents |
| WO2002060386A2 (en) * | 2001-02-01 | 2002-08-08 | Bristol-Myers Squibb Company | METHODS OF TREATING INFLAMMATORY AND IMMUNE DISEASES USING INHIBITORS OF IλB KINASE (IKK) |
| SI1401825T1 (sl) * | 2001-06-11 | 2010-01-29 | Virochem Pharma Inc | Tiofenski derivati kot protivirusna sredstva za flavirusno infekcijo |
| US8329924B2 (en) * | 2001-06-11 | 2012-12-11 | Vertex Pharmaceuticals (Canada) Incorporated | Compounds and methods for the treatment or prevention of Flavivirus infections |
| SE0102616D0 (sv) * | 2001-07-25 | 2001-07-25 | Astrazeneca Ab | Novel compounds |
| MXPA04002667A (es) * | 2001-09-19 | 2004-06-18 | Pharmacia Corp | Compuestos de pirazolilo sustituido para el tratamiento de la inflacion. |
| JP2005504806A (ja) * | 2001-09-21 | 2005-02-17 | スミスクライン・ビーチャム・コーポレイション | 化合物 |
| US7307097B2 (en) | 2001-09-27 | 2007-12-11 | Smithkline Beechman Corporation | Chemical compounds |
| DE60229975D1 (de) | 2001-10-04 | 2009-01-02 | Smithkline Beecham Corp | Nf-kb-inhibitoren |
| WO2003028731A1 (en) * | 2001-10-04 | 2003-04-10 | Smithkline Beecham Corporation | Chk1 kinase inhibitors |
| CA2464924A1 (en) * | 2001-10-30 | 2003-05-08 | Pharmacia Corporation | Heteroaromatic carboxamide derivatives for the treatment of inflammation |
| US7176314B2 (en) | 2001-12-05 | 2007-02-13 | Amgen, Inc. | Inflammation modulators |
| US6974870B2 (en) | 2002-06-06 | 2005-12-13 | Boehringer Ingelheim Phamaceuticals, Inc. | Substituted 3-amino-thieno [2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses |
| JP4364120B2 (ja) | 2002-06-06 | 2009-11-11 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 置換３−アミノ−チエノ［２，３−ｂ］ピリジン−２−カルボン酸アミド化合物、その製造方法及び使用 |
| EP1532133A4 (en) * | 2002-06-06 | 2006-11-15 | Smithkline Beecham Corp | NF-: B INHIBITORS |
| US7179836B2 (en) | 2002-09-20 | 2007-02-20 | Smithkline Beecham Corporation | Chemical compounds |
| CA2502429A1 (en) | 2002-10-31 | 2004-05-21 | Amgen Inc. | Antiinflammation agents |
| US7196106B2 (en) | 2002-11-05 | 2007-03-27 | Merck & Co., Inc | Cyanothiophene derivatives, compositions containing such compounds and methods of use |
| AU2003300832A1 (en) * | 2002-12-06 | 2004-06-30 | Smithkline Beecham Corporation | NF-KappaB INHIBITORS |
| DE60332482D1 (de) | 2002-12-10 | 2010-06-17 | Virochem Pharma Inc | Verbindungen und methoden zum behandeln oder vorbeugen von flavivirus infektionen |
| SE0300091D0 (sv) * | 2003-01-15 | 2003-01-15 | Astrazeneca Ab | Novel compounds |
| SE0300092D0 (sv) * | 2003-01-15 | 2003-01-15 | Astrazeneca Ab | Novel compounds |
| EP1660474B1 (en) | 2003-08-15 | 2008-10-29 | AstraZeneca AB | Substituted thiophenes and uses thereof |
| US20050085531A1 (en) * | 2003-10-03 | 2005-04-21 | Hodge Carl N. | Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
| ATE359283T1 (de) * | 2003-10-14 | 2007-05-15 | Pharmacia Corp | Substituierte pyrazinonverbindungen zur behandlung von entzündungen |
| WO2005037797A1 (en) * | 2003-10-21 | 2005-04-28 | Pharmacia Corporation | Substituted pyrazole urea compounds for the treatment of inflammation |
| EP1732920B1 (en) * | 2004-01-05 | 2011-03-09 | AstraZeneca AB | Thiophene derivatives as chk 1 inhibitors |
| CA2562827A1 (en) * | 2004-04-12 | 2005-10-27 | Sankyo Company Limited | Thienopyridine derivatives |
| WO2005105777A1 (en) * | 2004-05-05 | 2005-11-10 | Pharmacia & Upjohn Company Llc | Substituted thiophene amide compounds for the treatment of inflammation |
| PE20060373A1 (es) | 2004-06-24 | 2006-04-29 | Smithkline Beecham Corp | Derivados 3-piperidinil-7-carboxamida-indazol como inhibidores de la actividad cinasa de ikk2 |
| PE20060748A1 (es) | 2004-09-21 | 2006-10-01 | Smithkline Beecham Corp | Derivados de indolcarboxamida como inhibidores de quinasa ikk2 |
| WO2006036031A1 (ja) * | 2004-09-30 | 2006-04-06 | Takeda Pharmaceutical Company Limited | 縮合フラン誘導体およびその用途 |
| JP5000490B2 (ja) | 2005-04-28 | 2012-08-15 | 武田薬品工業株式会社 | チエノピリミドン化合物 |
| US8063071B2 (en) | 2007-10-31 | 2011-11-22 | GlaxoSmithKline, LLC | Chemical compounds |
| MX2007016541A (es) | 2005-06-30 | 2008-03-07 | Smithkline Beecham Corp | Compuestos quimicos. |
| WO2007146602A1 (en) | 2006-06-06 | 2007-12-21 | Boehringer Ingelheim International Gmbh | Substituted 3-amino-thieno[2,3-b] pyridine-2-carboxamide compounds, their preparation and use |
| AU2007321677B2 (en) | 2006-11-15 | 2013-04-11 | Vertex Pharmaceuticals (Canada) Incorporated | Thiophene analogues for the treatment or prevention of flavivirus infections |
| RU2470918C2 (ru) * | 2007-01-15 | 2012-12-27 | Сантен Фармасьютикал Ко., Лтд. | НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ОБЛАДАЮЩИЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ IκB КИНАЗЫ β |
| PE20081889A1 (es) | 2007-03-23 | 2009-03-05 | Smithkline Beecham Corp | Indol carboxamidas como inhibidores de ikk2 |
| GB0709031D0 (en) | 2007-05-10 | 2007-06-20 | Sareum Ltd | Pharmaceutical compounds |
| CA2721927C (en) | 2008-04-21 | 2014-01-28 | Otonomy, Inc. | Auris formulations for treating otic diseases and conditions |
| US11969501B2 (en) | 2008-04-21 | 2024-04-30 | Dompé Farmaceutici S.P.A. | Auris formulations for treating otic diseases and conditions |
| US8445529B2 (en) * | 2008-07-14 | 2013-05-21 | Santen Pharmaceutical Co., Ltd. | Indole derivative having, carbamoyl group, ureido group and substituted oxy group |
| JP2010077119A (ja) * | 2008-08-25 | 2010-04-08 | Santen Pharmaceut Co Ltd | ウレイド基、アミノカルボニル基及び置換フェニル基を置換基として有するピロール誘導体を有効成分として含有する骨・関節疾患の予防又は治療剤 |
| JP5492496B2 (ja) * | 2008-08-25 | 2014-05-14 | 参天製薬株式会社 | ウレイド基、アミノカルボニル基及び置換基を有してもよい二環式基を置換基として有する新規ピロール誘導体 |
| WO2010056720A1 (en) * | 2008-11-14 | 2010-05-20 | E. I. Du Pont De Nemours And Company | Method for preparing a non-hydratable crystal form |
| EP2406249A1 (en) | 2009-03-10 | 2012-01-18 | Glaxo Group Limited | Indole derivatives as ikk2 inhibitors |
| GB0913345D0 (en) | 2009-07-31 | 2009-09-16 | Astrazeneca Ab | New combination 802 |
| WO2011061527A1 (en) | 2009-11-17 | 2011-05-26 | Astrazeneca Ab | Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases |
| WO2012046793A1 (ja) * | 2010-10-07 | 2012-04-12 | 参天製薬株式会社 | ウレイド基とアミノカルボニル基を置換基として有するチオフェン誘導体を有効成分として含有する新規ｊａｋ３阻害剤 |
| GB201016912D0 (en) | 2010-10-07 | 2010-11-24 | Astrazeneca Ab | Novel combination |
| GB201021979D0 (en) | 2010-12-23 | 2011-02-02 | Astrazeneca Ab | New compound |
| GB201021992D0 (en) | 2010-12-23 | 2011-02-02 | Astrazeneca Ab | Compound |
| EP2520292A1 (en) | 2011-05-06 | 2012-11-07 | Helmholtz-Zentrum für Infektionsforschung GmbH | Use of spirangiens for the treatment or prevention of IL-8 or IL-6 mediated disorders |
| GB201202027D0 (en) | 2012-02-06 | 2012-03-21 | Sareum Ltd | Pharmaceutical compounds |
| ES2566205T3 (es) | 2012-03-02 | 2016-04-11 | Sareum Limited | Inhibidores de quinasa TYK2 |
| AU2017290256A1 (en) | 2016-06-29 | 2019-01-17 | Otonomy, Inc. | Triglyceride otic formulations and uses thereof |
| GB201617871D0 (en) | 2016-10-21 | 2016-12-07 | Sareum Limited | Pharmaceutical compounds |
| US11000491B2 (en) | 2017-05-05 | 2021-05-11 | Hepanova, Inc. | Amino-aryl-benzamide compounds and methods of use thereof |
| GB201816369D0 (en) | 2018-10-08 | 2018-11-28 | Sareum Ltd | Pharmaceutical compounds |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1468012A (en) | 1973-08-09 | 1977-03-23 | Beecham Group Ltd | 2-amino-3-carboxy-thiophene derivatives |
| DE3529247A1 (de) | 1985-05-17 | 1986-11-20 | Bayer Ag, 5090 Leverkusen | Verwendung von thienylharnstoffen und -isoharnstoffen als leistungsfoerdernde mittel bei tieren, neue thienylharnstoffe und -isoharnstoffe und ihre herstellung |
| US5258357A (en) * | 1989-10-07 | 1993-11-02 | Basf Aktiengesellschaft | Carboxamides, their preparation and their use as herbicides |
| US5378703A (en) * | 1990-04-09 | 1995-01-03 | Alcon Laboratories, Inc. | Sulfonamides useful as carbonic anhydrase inhibitors |
| US5571810A (en) * | 1990-06-11 | 1996-11-05 | Fujisawa Pharmaceutical Co., Ltd. | Thiophene derivatives |
| WO1998002430A1 (en) * | 1996-07-11 | 1998-01-22 | Pfizer Pharmaceuticals Inc. | Pyridylpyrrole compounds useful as interleukin- and tnf antagonists |
| PT853083E (pt) * | 1997-01-06 | 2001-12-28 | Pfizer | Composto de piridilfurano e piridiltiofeno e sua utilizacao farmaceutica |
| US6037340A (en) | 1997-05-28 | 2000-03-14 | Cadus Pharmaceutical Corporation | Synthesis and use of thiophene- and pyrrole-based heteroaromatic compounds |
| DE19744026A1 (de) * | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln |
| WO1999046244A1 (en) | 1998-03-12 | 1999-09-16 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (ptpases) |
| HN2000000051A (es) | 1999-05-19 | 2001-02-02 | Pfizer Prod Inc | Derivados heterociclicos utiles como agentes anticancerosos |
| US6414013B1 (en) | 2000-06-19 | 2002-07-02 | Pharmacia & Upjohn S.P.A. | Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention |
| JP2004523476A (ja) * | 2000-10-12 | 2004-08-05 | スミスクライン・ビーチャム・コーポレイション | ＮＦ−κＢ阻害剤 |
| US20040024047A1 (en) * | 2001-10-12 | 2004-02-05 | Callahan James F. | Nf-kb inhibitors |
| SE0102616D0 (sv) * | 2001-07-25 | 2001-07-25 | Astrazeneca Ab | Novel compounds |
| SE0102617D0 (sv) * | 2001-07-25 | 2001-07-25 | Astrazeneca Ab | Novel compounds |
| DE60229975D1 (de) * | 2001-10-04 | 2009-01-02 | Smithkline Beecham Corp | Nf-kb-inhibitoren |
| SE0300091D0 (sv) * | 2003-01-15 | 2003-01-15 | Astrazeneca Ab | Novel compounds |
-
2000
- 2000-02-12 GB GBGB0003154.2A patent/GB0003154D0/en not_active Ceased
-
2001
- 2001-02-07 AT AT01902951T patent/ATE266019T1/de active
- 2001-02-07 MX MXPA02007734A patent/MXPA02007734A/es active IP Right Grant
- 2001-02-07 EP EP01902951A patent/EP1261600B1/en not_active Expired - Lifetime
- 2001-02-07 AU AU30705/01A patent/AU781047B2/en not_active Ceased
- 2001-02-07 NZ NZ519947A patent/NZ519947A/en not_active IP Right Cessation
- 2001-02-07 DE DE60103132T patent/DE60103132T2/de not_active Expired - Lifetime
- 2001-02-07 BR BR0108143-8A patent/BR0108143A/pt not_active Application Discontinuation
- 2001-02-07 TR TR2004/01962T patent/TR200401962T4/xx unknown
- 2001-02-07 PT PT01902951T patent/PT1261600E/pt unknown
- 2001-02-07 US US09/868,884 patent/US7358376B2/en not_active Expired - Fee Related
- 2001-02-07 WO PCT/SE2001/000248 patent/WO2001058890A1/en not_active Ceased
- 2001-02-07 ES ES01902951T patent/ES2218376T3/es not_active Expired - Lifetime
- 2001-02-07 CA CA2396824A patent/CA2396824C/en not_active Expired - Fee Related
- 2001-02-07 KR KR1020027010124A patent/KR100738165B1/ko not_active Expired - Fee Related
- 2001-02-07 JP JP2001558440A patent/JP4812999B2/ja not_active Expired - Fee Related
- 2001-02-07 DK DK01902951T patent/DK1261600T3/da active
- 2001-02-07 IL IL15048201A patent/IL150482A0/xx active IP Right Grant
- 2001-02-07 CN CNB018046606A patent/CN1243747C/zh not_active Expired - Fee Related
-
2002
- 2002-06-27 IL IL150482A patent/IL150482A/en not_active IP Right Cessation
- 2002-07-02 ZA ZA200205300A patent/ZA200205300B/en unknown
- 2002-08-09 NO NO20023786A patent/NO327741B1/no not_active IP Right Cessation
-
2007
- 2007-12-03 US US11/949,273 patent/US20090181962A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PT1261600E (pt) | 2004-08-31 |
| NO20023786L (no) | 2002-09-23 |
| CN1425012A (zh) | 2003-06-18 |
| DE60103132D1 (de) | 2004-06-09 |
| US7358376B2 (en) | 2008-04-15 |
| US20090181962A1 (en) | 2009-07-16 |
| IL150482A (en) | 2006-08-01 |
| NO327741B1 (no) | 2009-09-14 |
| AU3070501A (en) | 2001-08-20 |
| CA2396824A1 (en) | 2001-08-16 |
| EP1261600B1 (en) | 2004-05-06 |
| CN1243747C (zh) | 2006-03-01 |
| ATE266019T1 (de) | 2004-05-15 |
| DK1261600T3 (da) | 2004-08-16 |
| NO20023786D0 (no) | 2002-08-09 |
| KR20030005183A (ko) | 2003-01-17 |
| KR100738165B1 (ko) | 2007-07-10 |
| WO2001058890A1 (en) | 2001-08-16 |
| CA2396824C (en) | 2010-11-16 |
| GB0003154D0 (en) | 2000-04-05 |
| BR0108143A (pt) | 2003-01-21 |
| NZ519947A (en) | 2004-05-28 |
| US20020107252A1 (en) | 2002-08-08 |
| DE60103132T2 (de) | 2005-05-12 |
| JP4812999B2 (ja) | 2011-11-09 |
| MXPA02007734A (es) | 2002-10-11 |
| TR200401962T4 (tr) | 2004-09-21 |
| EP1261600A1 (en) | 2002-12-04 |
| IL150482A0 (en) | 2002-12-01 |
| JP2003522766A (ja) | 2003-07-29 |
| ES2218376T3 (es) | 2004-11-16 |
| AU781047B2 (en) | 2005-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200205300B (en) | Heteroaromatic carboxamide derivatives and their use as inhibitors of the enzyme IKK-2. | |
| EP1421079B1 (en) | Thiophenyl compounds as medicaments | |
| ZA200400492B (en) | Novel compounds. | |
| US20100029754A1 (en) | Thiophene-carboxamide derivatives and their use as inhibitors of the enzyme ikk-2 | |
| JP2003522766A5 (enExample) | ||
| EP1444010A2 (en) | Heteroaromatic carboxamide derivatives for the treatment of inflammation | |
| JP4568714B2 (ja) | 酵素ｉｋｋ−２阻害剤としてのチオフェンカルボキサミド | |
| AU2002321970A1 (en) | Novel compounds |